Clinical trials: Internal Radiation, open to volunteers
Prostate Cancer
Focal Salvage Brachytherapy Study (FocaSaBra)
The aim of this prospective phase II study is to evaluate the toxicity of salvage partial (focal) prostate brachytherapy in patients after prior radiotherapy (standard teleradiotherapy with / without brachytherapy…
- Trial name
- FocaSaBra (NCT05715502)
- Testing
- brachytherapy
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- The Greater Poland Cancer Centre
Glioma
Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation
The goal of this clinical research study is to learn about the safety and effects of M032 given directly into the tumor in children and adults with DMG and who have received standard-of-care radiation therapy.
- Trial name
- NCT07076498
- Testing
- M032
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
High-grade Glioma, Medulloblastoma
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
The goal of this interventional study is to Assess the safety and tolerability of atovaquone in combination with standard radiation therapy (RT) for the treatment of pediatric patients with newly diagnosed pediatric high-grade…
- Conditions
- High-grade Glioma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
- Trial name
- AflacBT2303 (NCT06624371)
- Testing
- Atovaquone, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Emory University
Hepatocellular Carcinoma, Liver Cancer
Characterizing Tumor Hypoxia With BOLD-MRI to Predict Y-90 Treatment Response
The purpose of this study is to find out whether a special type of magnetic resonance imaging ( MRI), called blood oxygen level-dependent (BOLD) MRI, can help measure how much oxygen is present in liver tumors.
- Trial name
- BOLDMRI (NCT07916376)
- Testing
- Blood oxygen level-dependent (BOLD) magnetic resonance imaging ( MRI)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Uterine Cervical Neoplasm
Cervical Boost by Ablative Stereotactic Radiotherapy (SABR) vs Brachytherapy in Patients With Cervical Carcinoma
Background Cervical cancer (CaCu) is the fourth cause of death in women. In patients with locally advanced disease, the treatment of choice is CT/RT, followed by additional boosting with brachytherapy (BT).
- Trial name
- SABRVICAL (NCT06560697)
- Testing
- SABR VS Intracavitary 3D Brachytherapy
- Where
- Mexico
- Volunteers
- 84 people
- Sponsor
- National Institute of Cancerología
Carcinoma Nasal Vestibule
Brachytherapy (Interventional Radiotherapy) for Squamous Cell Carcinomas of the Nasal Vestibule: Optimization of Dose and Technique
Rationale: Primary brachytherapy (also known as Interventional Radiotherapy, IRT) achieves high cure rates in cancer of the nasal vestibule (CNV) while preserving nasal aesthetics and function.
- Trial name
- BRAVO (NCT07801690)
- Where
- Netherlands
- Volunteers
- 300 people
- Sponsor
- Radboud University Medical Center
Oligoprogressive Prostate Cancer, Metastatic Prostate Cancer
PSMA PET-Staged Comprehensive Progression-Directed Radiotherapy for Limited Progression in Prostate Cancer
PSMA-OLIGO-PRO is a multicenter, ambispective, observational real-world evidence registry of adults with metastatic hormone-sensitive or metastatic castration-resistant prostate cancer who develop a limited number of progressing…
- Trial name
- PSMA-OLIGO-PRO (NCT07691697)
- Testing
- Comprehensive Progression-Directed Radiotherapy
- Where
- Poland
- Volunteers
- 1,000 people
- Sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
Pancreatic Cancer
Central-boost Ablative Radiation Therapy for Solid Tumors (CBART)
In the case of large tumors or tumors closely adjacent to organs at risk, ablative doses offered by stereotactic body radiation therapy (SBRT) could not be delivered.
- Trial name
- NCT06427460
- Testing
- Central-boost ablative dose delivered by stereotactic body radiation therapy
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Changhai Hospital
Locally Advanced Cervical Carcinoma
Evaluation of Ultraaccelerated High Dose Rate Intrauterine Interventional Radiotherapy
To evaluate the degree of acute and long-term intestinal, urinary and vaginal toxicity, and the impact on sexual activity of an accelerated fractionation of high dose rate interventional radiotherapy (IRT-HDR) in patients with…
- Trial name
- EROS3 (NCT06398938)
- Testing
- Interventional Radiotherapy
- Where
- Italy
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rectal Cancer
A Phase II Prospective Study of Maastro Applicator Brachytherapy for Rectal Cancer
Rectal cancer is a common type of cancer and an important cause of illness and death worldwide. In 2020, cancers of the colon and rectum were the fourth most common cancers globally, and about one third of these cases were rectal…
- Trial name
- NCT07402486
- Testing
- Rectal HDR brachytherapy via Maastro Applicator
- Volunteers
- 20 people
- Sponsor
- Siriraj Hospital
Cervical Carcinoma
Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer
Radiotherapy result in tumor cell death by creating an immune potentiation effect, but can also lead to long lasting immune suppression.
- Trial name
- STIRR (NCT06804135)
- Where
- India
- Volunteers
- 110 people
- Sponsor
- Tata Memorial Hospital
Gynecologic Cancer
3DUS Imaging of Needles in Gynecological Brachytherapy
Brachytherapy treatment in gynecological cancers is an essential component to delivering adequate doses of radiation to a tumour while sparing normal tissue.
- Trial name
- NCT04705467
- Testing
- Gynecological brachytherapy
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Western University, Canada
Metastatic Castration-resistant Prostate Cancer
Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer
Prostate cancer is the third leading cause of cancer-related death in men in the United States and Europe. The treatment of metastatic castration-resistant prostate cancer (mCRPC) has evolved with the arrival of the radioligand…
- Trial name
- ReaLuP (NCT06866938)
- Testing
- [177Lu]Lu-PSMA-617 (Pluvicto, Novartis)
- Where
- 16 sites in France
- Volunteers
- 58 people
- Sponsor
- Hospices Civils de Lyon
Cervival Cancer
Hypofractionated Chemoradiotherapy for Cervical Cancer
The goal of this clinical trial is to evaluate whether hypofractionated whole pelvic or extended-field concurrent chemoradiotherapy can improve treatment access and efficiency while potentially providing superior oncologic…
- Trial name
- HYPOCx (NCT07709650)
- Testing
- Hypofractionated Chemoradiotherapy, Conventional Chemoradiotherapy, Concurrent chemotherapy
- Where
- Thailand
- Volunteers
- 250 people
- Sponsor
- Mahidol University
Breast Cancer
Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy
The aim of this study is to explore the impact of internal mammary nodal irradiation on disease-free survival in high-risk breast cancer patients (ypN+or supra/subclavicular lymph node positive) after neoadjuvant chemotherapy.
- Trial name
- NCT06559696
- Testing
- internal mammary nodal irradiation, No internal mammary node irradiation
- Where
- China
- Volunteers
- 722 people, healthy volunteers welcome
- Sponsor
- Fujian Medical University Union Hospital
Prostate Cancer, Brachytherapy
PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer
PRO-BOOST-N is a prospective, multicenter, randomized phase II/III clinical trial for patients with prostate cancer and pelvic lymph node involvement (cN1M0) confirmed by PSMA PET/CT, without distant metastatic disease.
- Conditions
- Prostate Cancer, Brachytherapy, Stereotactic Body Radiation Therapy (SBRT), Dose Escalation: Solid Tumors
- Trial name
- PRO-BOOST-N (NCT07426094)
- Testing
- Ultrahypofractionated Whole-Pelvis Radiotherapy, SBRT-Based Prostate Radiotherapy (No Boost), Ablative Prostate Boost
- Where
- Poland
- Volunteers
- 600 people
- Sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
Locally Advanced Rectal Cancer
Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer
This is a small Phase II study testing whether targeted internal radiation treatment (HDREBT) followed by two doses of the immunotherapy drug Nivolumab is safe, practical, and potentially effective before patients undergo surgery…
- Trial name
- IMPERIA (NCT07645118)
- Testing
- Nivolumab, HDRBET, Total Mesorectal Excision (TME)
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Dr. Te Vuong
Patients With Prostate Cancer
High-Dose-Rate Brachytherapy
This pilot study initiates a research program testing the early technical and clinical performance of a novel procedure for MRI-guided high-dose-rate (HDR) prostate brachytherapy. Testing will proceed in two cohorts of patients.
- Trial name
- NCT00913939
- Testing
- MRI Guided Needles to deliver HDR Brachytherapy
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- University Health Network, Toronto
LOCALLY ADVANCED CERVICAL CANCERS
Outcomes of Image-guided High-dose-rate Uterovaginal Brachytherapy With Single Implantation
Background and Rationale: Locally advanced cervical cancer remains a major public health concern worldwide and in France. Standard-of-care management involves concurrent chemoradiotherapy followed by brachytherapy, which is…
- Trial name
- UNICURE-HD (NCT07213427)
- Testing
- data collection
- Volunteers
- 363 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Prostate Carcinoma, Stage I Prostate Cancer AJCC v8
CT- Versus MRI-Based Planning for High-Dose-Rate Prostate Brachytherapy for Prostate Cancer
This clinical trial studies the safety of a computed tomography (CT) scan, with or without a magnetic resonance imaging (MRI) scan, in planning for high-dose-rate (HDR) prostate brachytherapy treatment in patients with prostate…
- Conditions
- Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
- Trial name
- NCT07859722
- Testing
- Magnetic Resonance Imaging, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Emory University